Back To Search
Manish J Dave MD

Manish J. Dave, MD

  • Hematology | Medical Oncology
(973) 322-5200
Languages Spoken English, Gujarati, Hindi, Spanish
See This Doctor
  • At A Glance
  • Education & Publications
  • Insurance
  • Hospital Affiliations
    Bio

    I have an interest in clinical trials and the newest available targeted therapies. I have given multiple presentations and published numerous clinical and basic science research articles on both solid and hematologic malignancies. I have helped provide medical care to underserved residents of Winston-Salem, NC and Mumbai, India.

    Philosophy of Care Statement

    I treat both benign blood disorders and cancer, and I am devoted to providing compassionate care to my patients. My philosophy is to treat every patient as I would treat my own family member. I strive to provide the best and newest available therapy for my patients.

    Clinical Interests

    Procedures:

    Bone marrow aspirate & biopsy, intrathecal chemotherapy, lumbar puncture

    Conditions:

    Leukemia, lymphoma, multiple myeloma, lung cancer, prostate cancer, breast cancer, renal cancer, brain tumors, sarcoma, skin cancer, thyroid cancer, thymomas

  • Medical School

    Wake Forest University School of Medicine - 2011
    NC

    Internship

    Rush University Medical Center - 2012

    Residency

    Rush University Medical Center - 2014

    Fellowship

    Albert Einstein College of Medicine - 2017

    Publications
    • Title:The effect of deep brain stimulation on voiding dysfunction in Parkinson’s Disease and essential tremor.
      Authors:Vishwajit S, Dave M, Case D, Siddiqui M, Badlani G.
      Publisher:The Journal of Urology
      Date:2009
      Issue:Apr; 181(4): 673-674.
      Description:
    • Title:Treatment of Recurrent Pediatric Gastrointestinal Stromal Tumors.
      Authors:Dave M, Jimenez A, Evans K, Leslie W.
      Publisher:Gastrointestinal Cancer Research.
      Date:2012
      Issue:Jul-Aug; 5(4): 139–140.
      Description:
    • Title:EGFR gene mutation and epithelial to mesenchymal transition (EMT) markers in advanced NSCLC patients treated with erlotinib.
      Authors:Fidler MJ, Dave M, Basu S, Hensing TA, Pool M, Mahon B, Borgia JA, Walters KK, Escarzaga D, Batus M, Bonomi PD.
      Publisher:J Clin Oncol
      Date:2012
      Issue:suppl; abstr e18117
      Description:
    • Title:The effect of BMI on systemic toxicity in AML patients receiving chemotherapy.
      Authors:Dave M, Burhani M, Venugopal P, Larson M.
      Publisher:J Clin Oncol
      Date:2013
      Issue:suppl; abstr 7108
      Description:
    • Title:Influence of BMI on outcomes of high-dose cytarabine and mitoxantrone induction therapy for AML.
      Authors:Burhani M, Dave M, Venugopal P, Larson M.
      Publisher:J Clin Oncol
      Date:2013
      Issue:suppl; abstr 7106
      Description:
    • Title:Classical Hodgkin’s Lymphoma Presenting with Hemophagocytosis.
      Authors:Dave M, Khedimi R, Averbukh Y.
      Publisher:MOJ Auto Dis
      Date:
      Issue:1(1): 00002.
      Description:
  • Insurance

    Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with a physician office that they are still a participating provider.

    • Aetna
    • Amerihealth
    • Cigna
    • Horizon BCBS
    • Medicaid
    • Medicare